PLAN-LES-OUATES GENEVA, SWITZERLAND -- (Marketwire) -- 07/03/09 --

Geneva, Switzerland, 2 July 2009 - Allosteric modulation company Addex Pharmaceuticals (SIX: ADXN) invites investors, analysts, media and other interested parties to attend its annual R&D day on Thursday, July 16, 2009 in Geneva, Switzerland. Addex management will discuss advances made with its small molecule allosteric modulator drug discovery platform as well as the status of multiple drug candidates, including the clinical-stage products ADX10059, ADX48621 and ADX71149, which are in development for gastroesophageal reflux disease (GERD), migraine prevention, Parkinson's disease, schizophrenia and anxiety. Addex also will disclose new early stage programs for important indications in metabolic disease and inflammation.

What:              Addex Pharmaceuticals R&D Day
When:              11:00am CCET  to 3:30pm  CET, July  16, 2009
Where:             14, Chemin des Aulx
                   1228 Plan-les-Ouates, Geneva
                   Switzerland

Interested parties are encouraged to attend in person. A complete program will be made available on our website prior to the event.

Please email investor.relations@addexpharma.com or media.relations@addexpharma.com for more information.

The Addex R&D Day presentations, related question and answer sessions and supporting documents will be webcast live and made available thereafter via www.addexpharma.com.

Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. Our lead allosteric modulator product, ADX10059, has achieved clinical proof of concept and is in Phase IIb testing for the treatment of GERD and, separately, migraine headache. Both are important diseases for which existing products with limited efficacy have established multi-billion dollar markets despite sub-optimal efficacy. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeutic strategy that also is being pursued in multiple indications by large pharma competitors.

Our products and technology already have proven their value through our partnerships with four of the top 10 pharmaceutical companies in the world. Specifically, an agreement with Ortho-McNeil-Janssen Inc. is focused on development of allosteric modulators to treat anxiety and schizophrenia. In addition, in two separate agreements with Merck & Co., Inc., we are developing allosteric modulators as drugs to treat Parkinson's disease and schizophrenia, respectively. Finally, GlaxoSmithKline and Roche have made equity investments in Addex.

Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com

Disclaimer

The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals Ltd is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.